Kumar, S. K. et al. Multiple myeloma. Night. Rev. Haze. Primers 317046 (2017).
Google Scholar
Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26149–157 (2012).
Google Scholar
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20359–371 (2023).
Google Scholar
Yu, B., Jiang, T. & Liu, D. BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol. 13125 (2020).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384705–716 (2021).
Google Scholar
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398314–324 (2021).
Google Scholar
Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood 1372890–2901 (2021).
Google Scholar
Chen, W. et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma. Exp. Hematol. Oncol.14119 (2025).
Locke, F. L. et al. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 92663–2676 (2025).
Google Scholar
Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19342–355 (2022).
Google Scholar
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. With. 221e20230903 (2024).
Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Night. With. 29422–429 (2023).
Google Scholar
Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Night. With. 30772–784 (2024).
Google Scholar
Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Night. With. 291379–1388 (2023).
Google Scholar
Diorio, C., Teachey, D. T. & Grupp, S. A. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat. Rev. Clin. Oncol. 2210–27 (2025).
Google Scholar
Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614635–648 (2023).
Google Scholar
Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 3881311–1317 (2025).
Google Scholar
Nicolai, C. J. et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144977–987 (2024).
Google Scholar
Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11119 (2021).
Google Scholar
Bozza, M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7eabf1333 (2021).
Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 37591–96 (2022).
Google Scholar
Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406228−231 (2025).
Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105297–316 (2020).
Google Scholar
Fan, H. et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biol. With. 2077–87 (2023).
Google Scholar
Tang, W. et al. Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China. Front. Pharmacol. 14979111 (2023).
Google Scholar
Cowan, A. J. et al. The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biol. Blood Marrow Transplant. 262372–2377 (2020).
Google Scholar
Milani, M. et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci. Transl. Med. 11eaav7325 (2019).
Milani, M. et al. Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol. With. 91558–1573 (2017).
Google Scholar
Wang, Y. & Shao, W. Innate immune response to viral vectors in gene therapy. Viruses 151801 (2023).
Kim, J. T. et al. Dendritic cell−targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci. Immunol. 2eaal1329 (2017).
Ganaie, S. S., Wang, Z., Su, B. & Mir, S. Editorial: Virus-induced innate immune response and inflammation. Front. Microbiol. 141213270 (2023).
Google Scholar
Huang, J., Rong, L., Wang, E. & Fang, Y. Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy. Immunotherapy 135–10 (2021).
Google Scholar
Danylesko, I. et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 561134–1143 (2021).
Google Scholar
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 1436–49 (2014).
Google Scholar
Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40367 (2021).
Google Scholar
Butman, J. et al. Steroid prophylaxis in patients receiving CAR T-cell therapy for relapsed and refractory non-Hodgkin lymphoma. Blood 1444507–4507 (2024).
Google Scholar
Costa, B. A. et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 1484 (2024).
Google Scholar
Li, C. et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 101681–1688 (2024).
Google Scholar
Dogan, A. et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 1073 (2020).
Google Scholar
Kim, I., Wu, G., Chai, N., Jordan, S. & Klein, A. Dynamic BCMA expression by alloreactive B cells coupled with donor specific antibody production during de novo alloantibody responses. J. Heart Lung Transplant. 38S249 (2019).
Google Scholar
Martin, J. et al. B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus. Int. J. Mol. Sci. 2510845 (2024).
Google Scholar
Maeda, K. et al. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1. Who animals. Blood 1134534–4540 (2009).
Google Scholar
Sun, Y. et al. Early B lymphocyte subsets in blood predict prognosis in sepsis. Front. Immunol. 151437864 (2024).
Google Scholar
Wang, X. et al. Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Discov. 760 (2021).
Google Scholar
Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 3801726–1737 (2019).
Google Scholar
Martin, N. et al. Idecabtagene vicleucel (ide-cel, bb2121) responses are characterized by early and temporally consistent activation and expansion of CAR T cells with a T effector phenotype. Blood 13617–18 (2020).
Google Scholar
Wright, J. F. Quantification of CpG motifs in rAAV genomes: avoiding the Toll. Mol. Ther. 281756–1758 (2020).
Google Scholar
Paremskaia, A. I. et al. Codon-optimization in gene therapy: promises, prospects and challenges. Front. Bioeng. Biotechnol. 121371596 (2024).
Google Scholar
Yoshida, T. et al. Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation. Sci. Rep. 1411540 (2024).
Google Scholar
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17e328–e346 (2016).
Google Scholar
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25625–638 (2019).
Google Scholar
